MedTrace Logo

PD-1 Antibody Combined Neoadjuvant Chemotherapy for Ovarian Cancer

NCT04815408 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2021-03-25

No results posted yet for this study

Summary

The main purpose of this study is to validate the efficacy and safety of anti-PD-1 in combination with neoadjuvant chemotherapy in women with advanced ovarian cancer.

Conditions

  • Ovarian Cancer
  • Neoadjuvant Chemotherapy
  • Anti-PD-1
  • Neoadjuvant Immunotherapy

Interventions

DRUG

BGB-A317

PD-1 antibody，Tislelizumab (BGB-A317)

DRUG

albumin-bound paclitaxel 260mg/m2 , Carboplatin AUC 5

albumin-bound paclitaxel 260mg/m2 , Carboplatin AUC 5

Sponsors & Collaborators

  • Second Affiliated Hospital, School of Medicine, Zhejiang University

    lead OTHER

Principal Investigators

  • Jianwei Zhou, MD · Second Affiliated Hospital of Zhejiang University School of Medicine

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-04-01
Primary Completion
2023-04-01
Completion
2025-04-01

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04815408 on ClinicalTrials.gov